BioReliance (Merck)

Glasgow, UK · Rockville, MD
Find alternatives to BioReliance (Merck) for AAV →
Hybrid — also manufactures internal programs
Program data pending ClinicalTrials.gov matching · Last scored 2026-11-12
80.3
Signal Score
✓ FDA Inspections (6) ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ✓ MHRA GMP (10) ✓ HC GMP (49)

Quick Facts: BioReliance (Merck)

Signal Score
80.3/100 (as of 2026-11-12)
Quality Compliance
97.2/100 — Clean MHRA record: 10 compliant GMP certificates (no deductions)
Headquarters
Glasgow, UK · Rockville, MD
Modalities
AAV, Lentiviral, Biologics
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About BioReliance (Merck)

Hybrid developer + CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 97.2
Clean MHRA record: 10 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, MHRA GMDP
Clean MHRA record: 10 compliant GMP certificates (no deductions)
FDA Inspections6 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2026-05-13)
MHRA GMP Certificates10 on record
Most Recent HC OutcomeCompliant · 2026-03-27
HC Attribution49 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean MHRA record: 10 compliant GMP certificates (no deductions)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Biologics
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 68.0
Parent company: Merck KGaA
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Merck KGaA
Financial assessment: 68.0/100
Capacity 63.0
3 manufacturing sites
Sites: Glasgow, UK, Rockville, MD, Stirling, UK
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
3 manufacturing sites

BioReliance (Merck) FDA Inspection History

2026-05
2026-01
2025-12
2024-11
2023-11
2023-08
NAI VAI OAI
Date Site Type 483 citations posted Classification
2026-05-13
Bioreliance Ltd.
Glasgow Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2026-01-29
BioReliance Corporation
Rockville, Maryland Facility-linked
Bioresearch Monitoring Yes Voluntary Action Indicated (VAI)
2025-12-05
Bioreliance Ltd.
Glasgow Facility-linked
Vaccines and Allergenic Products Not posted Voluntary Action Indicated (VAI)
2024-11-22
BioReliance Corporation
Rockville, Maryland Facility-linked
Vaccines and Allergenic Products Yes Voluntary Action Indicated (VAI)
2023-11-07
Bioreliance Ltd.
Glasgow Facility-linked
Vaccines and Allergenic Products Not posted No Action Indicated (NAI)
2023-08-04
BioReliance Corporation
Rockville, Maryland Facility-linked
Drug Quality Assurance Not posted No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

BioReliance (Merck) FDA 483 Findings 3 observations · 2024-11-22 → 2026-01-29 ?

By subsystem

  • CAPA 2 (66.7%)
  • Other 1 (33.3%)

By severity

  • 3 — Moderate: 2
  • 2 — Minor: 1
  • Repeat observations: 0

Most severe findings

  • Moderate (3) CAPA 2026-01-29 21 CFR 58.33(c)
    Study director: unforeseen circumstances

    "The study director failed to assure that unforeseen circumstances that might affect the quality and integrity of the nonclinical laboratory study were noted when they occurred and corrective action was taken and documented."

  • Moderate (3) CAPA 2024-11-22 21 CFR 211.192
    Investigations of discrepancies, failures

    "There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed."

  • Minor (2) Other 2026-01-29 21 CFR 58.33(a)
    Study director: follow study protocol

    "The study director failed to assure that the protocol, including any change, was approved and was followed."

BioReliance (Merck) MHRA GMP Compliance 10 certificates

2026-05
2026-05
2025-05
2025-05
2025-03
2025-03
2025-02
2025-02
2013-07
2012-07
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK API 22774 Insp GMP 22774/4473-0034 BIORELIANCE LIMITED GLASGOW G20 0XA 2026-05-12 COMPLIANT
UK MIA 22774 Insp GMP 22774/4473-0034[H] BIORELIANCE LIMITED GLASGOW G20 0XA 2026-05-12 COMPLIANT
UK GMP 22774 Insp GMP/IMP 22774/31007-0023 [H] BIORELIANCE LIMITED STIRLING FK9 4NF 2025-05-02 COMPLIANT
UK GMP 22774 Insp GMP/IMP 22774/31007-0023 [V] BIORELIANCE LIMITED STIRLING FK9 4NF 2025-05-02 COMPLIANT
UK GMP 22774 Insp GMP/IMP 22774/2062763-0012 [H] BIORELIANCE LIMITED PENICUIK EH26 0PZ 2025-03-19 COMPLIANT
UK GMP 22774 Insp GMP/IMP 22774/2062763-0012 [V] BIORELIANCE LIMITED PENICUIK EH26 0PZ 2025-03-19 COMPLIANT
UK MIA 22774 Insp GMP 13987/4473-0031[H] BIORELIANCE LIMITED GLASGOW G20 0XA 2025-02-13 COMPLIANT
UK API 22774 Insp GMP 13987/4473-0031 BIORELIANCE LIMITED GLASGOW G20 0XA 2025-02-13 COMPLIANT
UK GMP 18729 Insp GMP 18729/376405-0002[H] BIORELIANCE CORPORATION 20850-3349 2013-07-15 COMPLIANT
UK MIA 22774 Insp GMP/IMP 22774/31007-0012[H] BIORELIANCE LIMITED STIRLING FK9 4NF 2012-07-25 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Hiring Activity 16 open roles Beta

From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
16
open roles
5
in manufacturing, quality, PD/MSAT, engineering or regulatory (31%)
Trend from Nov 29, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 28, 2027.
Since Nov 19, 2026: 0 new postings, 882 taken down.
By function
Quality (QA / QC) 4
Process development & MSAT 1
Commercial, BD & client projects 8
Other (finance, HR, IT, other) 3
By site
Rockville, Maryland, United States profile site
· 4 QA/QC · 1 PD/MSAT · 8 other
13
Glasgow, Glasgow, United Kingdom profile site
· 3 other
3
Latest postings
Senior QC Specialist Quality (QA / QC) · Rockville, Maryland, United States
Quality Specialist 3 Systems Validation Quality (QA / QC) · Rockville, Maryland, United States
Strategic Account Executive Commercial, BD & client projects · Glasgow, Glasgow, United Kingdom
Chief of Staff BioReliance Testing Services Other (finance, HR, IT, other) · Rockville, Maryland, United States
Field Marketing Manager Commercial, BD & client projects · Glasgow, Glasgow, United Kingdom · posted Nov 17, 2026
Business Development Manager Commercial, BD & client projects · Glasgow, Glasgow, United Kingdom · posted Nov 17, 2026
Associate Scientist 2 Process development & MSAT · Rockville, Maryland, United States
Business Development Manager Southwest Commercial, BD & client projects · Rockville, Maryland, United States · posted Nov 10, 2026
Field Marketing Manager Commercial, BD & client projects · Rockville, Maryland, United States
Business Development Manager Midwest Commercial, BD & client projects · Rockville, Maryland, United States
Strategic Account Executive Commercial, BD & client projects · Rockville, Maryland, United States · posted Nov 5, 2026
Quality Assurance Specialist 2 Quality (QA / QC) · Rockville, Maryland, United States · posted Nov 3, 2026
Coverage: read from the parent company's careers board and kept only postings at this business's sites (BioReliance testing sites (Rockville, Glasgow/Stirling); needs JSON-LD locations). Roles outside those sites are left out, and some of this unit's roles may be missed. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: careers.emdgroup.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Frequently Asked Questions About BioReliance (Merck)

How many FDA inspections does BioReliance (Merck) have on record?
CDMO Signal tracks 6 FDA inspections for BioReliance (Merck), sourced from the FDA inspection database. See the full inspection history above.
Has BioReliance (Merck) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for BioReliance (Merck).
Does BioReliance (Merck) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 10 MHRA GMP certificates for BioReliance (Merck).
What is BioReliance (Merck)'s CDMO Signal Score?
BioReliance (Merck) has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating BioReliance (Merck) for a manufacturing program?
Use the free AI matchmaker to compare BioReliance (Merck) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Biologics CDMOs →

Similar CDMOs

ProBioGen
Berlin, DE
Signal Score: 78.1
AAV, Lentiviral, Biologics
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 83.5
Oligonucleotide, Biologics, AAV

Compare BioReliance (Merck) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on BioReliance (Merck)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.